Floatz logo

Apl-4098

Myelodysplastic Syndrome With Excess Blasts

Apollo Therapeutics LtdPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Myelodysplastic Syndrome With Excess Blasts cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
University of Southern California
Phase 3BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BB
TACROLIMUS
Fred Hutchinson Cancer Center
Phase 2BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Apl-4098 is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
CC
Indicative ·
43 / 100
View asset →
Acute Myeloid Leukemia (AML)Dormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →